Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models

Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropathology and applied neurobiology 2021-02, Vol.47 (1), p.43-60
Hauptverfasser: La Vitola, P., Balducci, C., Baroni, M., Artioli, L., Santamaria, G., Castiglioni, M., Cerovic, M., Colombo, L., Caldinelli, L., Pollegioni, L., Forloni, G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 60
container_issue 1
container_start_page 43
container_title Neuropathology and applied neurobiology
container_volume 47
creator La Vitola, P.
Balducci, C.
Baroni, M.
Artioli, L.
Santamaria, G.
Castiglioni, M.
Cerovic, M.
Colombo, L.
Caldinelli, L.
Pollegioni, L.
Forloni, G.
description Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking. Methods To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice. Results Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice. Conclusions The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.
doi_str_mv 10.1111/nan.12644
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2426177441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426177441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</originalsourceid><addsrcrecordid>eNp10M0uBTEYxvFGCMfHwg3IJBZYDO20pzNdnoivRLBgPanOW0qnPdqZMDuX4FbciItwJcrBQqKbbn75582D0DrBuyS9PSfdLik4Y3NoRCgf54UQeB6NMMXjnFSML6HlGO8wxuOSi0W0RAsuuBBihJoLCGZ6C0HazDhtZdvKzniXwZNUEK5lBzF7e31_fomD65UF47LOPxlluiGTrskc9MFPZXfrrb8ZUiO7kOHeuOjdVsxa34CNq2hBSxth7ftfQVeHB5f7x_np-dHJ_uQ0V3RMWa6plkAV1pJXSjUCcCMYrxhJZ5eKcqwrSgTHApgsm5JWVQFMKK2pLBhhiq6g7Vl3GvxDD7GrWxMVWCsd-D7WBSs4KUvGSKKbf-id74NL1yVVFZRwQUVSOzOlgo8xgK6nwbQyDDXB9ef0dZq-_po-2Y3vYn_dQvMrf7ZOYG8GHo2F4f9SfTY5myU_AKmhkAE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482316939</pqid></control><display><type>article</type><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</creator><creatorcontrib>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</creatorcontrib><description>Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking. Methods To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice. Results Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice. Conclusions The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</description><identifier>ISSN: 0305-1846</identifier><identifier>EISSN: 1365-2990</identifier><identifier>DOI: 10.1111/nan.12644</identifier><identifier>PMID: 32696999</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>alpha-Synuclein - metabolism ; alpha-Synuclein - pharmacology ; Animal models ; Animals ; Astrocytes ; Astrocytes - metabolism ; Axons ; Cognitive ability ; Disease Models, Animal ; Environmental factors ; Glial cells ; Inflammation ; Inflammation - pathology ; Lewy bodies ; Lipopolysaccharides ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microglia ; Microglia - pathology ; Movement disorders ; Nerve Degeneration - drug therapy ; Nerve Degeneration - pathology ; Nervous System Diseases - pathology ; Neurodegenerative diseases ; neuroinflammation ; Neurotoxicity ; nonmotor deficits ; oligomeropathies ; Parkinson Disease - metabolism ; Parkinson Disease - pathology ; Parkinson's disease ; Phenotypes ; Substantia Nigra - drug effects ; Substantia Nigra - pathology ; Synuclein ; Transgenic mice ; α‐synuclein oligomers</subject><ispartof>Neuropathology and applied neurobiology, 2021-02, Vol.47 (1), p.43-60</ispartof><rights>2020 British Neuropathological Society</rights><rights>2020 British Neuropathological Society.</rights><rights>Copyright © 2021 British Neuropathological Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</citedby><cites>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</cites><orcidid>0000-0001-5374-3914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnan.12644$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnan.12644$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32696999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>La Vitola, P.</creatorcontrib><creatorcontrib>Balducci, C.</creatorcontrib><creatorcontrib>Baroni, M.</creatorcontrib><creatorcontrib>Artioli, L.</creatorcontrib><creatorcontrib>Santamaria, G.</creatorcontrib><creatorcontrib>Castiglioni, M.</creatorcontrib><creatorcontrib>Cerovic, M.</creatorcontrib><creatorcontrib>Colombo, L.</creatorcontrib><creatorcontrib>Caldinelli, L.</creatorcontrib><creatorcontrib>Pollegioni, L.</creatorcontrib><creatorcontrib>Forloni, G.</creatorcontrib><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><title>Neuropathology and applied neurobiology</title><addtitle>Neuropathol Appl Neurobiol</addtitle><description>Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking. Methods To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice. Results Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice. Conclusions The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</description><subject>alpha-Synuclein - metabolism</subject><subject>alpha-Synuclein - pharmacology</subject><subject>Animal models</subject><subject>Animals</subject><subject>Astrocytes</subject><subject>Astrocytes - metabolism</subject><subject>Axons</subject><subject>Cognitive ability</subject><subject>Disease Models, Animal</subject><subject>Environmental factors</subject><subject>Glial cells</subject><subject>Inflammation</subject><subject>Inflammation - pathology</subject><subject>Lewy bodies</subject><subject>Lipopolysaccharides</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Microglia</subject><subject>Microglia - pathology</subject><subject>Movement disorders</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - pathology</subject><subject>Nervous System Diseases - pathology</subject><subject>Neurodegenerative diseases</subject><subject>neuroinflammation</subject><subject>Neurotoxicity</subject><subject>nonmotor deficits</subject><subject>oligomeropathies</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - pathology</subject><subject>Parkinson's disease</subject><subject>Phenotypes</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - pathology</subject><subject>Synuclein</subject><subject>Transgenic mice</subject><subject>α‐synuclein oligomers</subject><issn>0305-1846</issn><issn>1365-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M0uBTEYxvFGCMfHwg3IJBZYDO20pzNdnoivRLBgPanOW0qnPdqZMDuX4FbciItwJcrBQqKbbn75582D0DrBuyS9PSfdLik4Y3NoRCgf54UQeB6NMMXjnFSML6HlGO8wxuOSi0W0RAsuuBBihJoLCGZ6C0HazDhtZdvKzniXwZNUEK5lBzF7e31_fomD65UF47LOPxlluiGTrskc9MFPZXfrrb8ZUiO7kOHeuOjdVsxa34CNq2hBSxth7ftfQVeHB5f7x_np-dHJ_uQ0V3RMWa6plkAV1pJXSjUCcCMYrxhJZ5eKcqwrSgTHApgsm5JWVQFMKK2pLBhhiq6g7Vl3GvxDD7GrWxMVWCsd-D7WBSs4KUvGSKKbf-id74NL1yVVFZRwQUVSOzOlgo8xgK6nwbQyDDXB9ef0dZq-_po-2Y3vYn_dQvMrf7ZOYG8GHo2F4f9SfTY5myU_AKmhkAE</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>La Vitola, P.</creator><creator>Balducci, C.</creator><creator>Baroni, M.</creator><creator>Artioli, L.</creator><creator>Santamaria, G.</creator><creator>Castiglioni, M.</creator><creator>Cerovic, M.</creator><creator>Colombo, L.</creator><creator>Caldinelli, L.</creator><creator>Pollegioni, L.</creator><creator>Forloni, G.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5374-3914</orcidid></search><sort><creationdate>202102</creationdate><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><author>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>alpha-Synuclein - metabolism</topic><topic>alpha-Synuclein - pharmacology</topic><topic>Animal models</topic><topic>Animals</topic><topic>Astrocytes</topic><topic>Astrocytes - metabolism</topic><topic>Axons</topic><topic>Cognitive ability</topic><topic>Disease Models, Animal</topic><topic>Environmental factors</topic><topic>Glial cells</topic><topic>Inflammation</topic><topic>Inflammation - pathology</topic><topic>Lewy bodies</topic><topic>Lipopolysaccharides</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Microglia</topic><topic>Microglia - pathology</topic><topic>Movement disorders</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - pathology</topic><topic>Nervous System Diseases - pathology</topic><topic>Neurodegenerative diseases</topic><topic>neuroinflammation</topic><topic>Neurotoxicity</topic><topic>nonmotor deficits</topic><topic>oligomeropathies</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - pathology</topic><topic>Parkinson's disease</topic><topic>Phenotypes</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - pathology</topic><topic>Synuclein</topic><topic>Transgenic mice</topic><topic>α‐synuclein oligomers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>La Vitola, P.</creatorcontrib><creatorcontrib>Balducci, C.</creatorcontrib><creatorcontrib>Baroni, M.</creatorcontrib><creatorcontrib>Artioli, L.</creatorcontrib><creatorcontrib>Santamaria, G.</creatorcontrib><creatorcontrib>Castiglioni, M.</creatorcontrib><creatorcontrib>Cerovic, M.</creatorcontrib><creatorcontrib>Colombo, L.</creatorcontrib><creatorcontrib>Caldinelli, L.</creatorcontrib><creatorcontrib>Pollegioni, L.</creatorcontrib><creatorcontrib>Forloni, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropathology and applied neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>La Vitola, P.</au><au>Balducci, C.</au><au>Baroni, M.</au><au>Artioli, L.</au><au>Santamaria, G.</au><au>Castiglioni, M.</au><au>Cerovic, M.</au><au>Colombo, L.</au><au>Caldinelli, L.</au><au>Pollegioni, L.</au><au>Forloni, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</atitle><jtitle>Neuropathology and applied neurobiology</jtitle><addtitle>Neuropathol Appl Neurobiol</addtitle><date>2021-02</date><risdate>2021</risdate><volume>47</volume><issue>1</issue><spage>43</spage><epage>60</epage><pages>43-60</pages><issn>0305-1846</issn><eissn>1365-2990</eissn><abstract>Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking. Methods To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice. Results Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice. Conclusions The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32696999</pmid><doi>10.1111/nan.12644</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0001-5374-3914</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0305-1846
ispartof Neuropathology and applied neurobiology, 2021-02, Vol.47 (1), p.43-60
issn 0305-1846
1365-2990
language eng
recordid cdi_proquest_miscellaneous_2426177441
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects alpha-Synuclein - metabolism
alpha-Synuclein - pharmacology
Animal models
Animals
Astrocytes
Astrocytes - metabolism
Axons
Cognitive ability
Disease Models, Animal
Environmental factors
Glial cells
Inflammation
Inflammation - pathology
Lewy bodies
Lipopolysaccharides
Mice
Mice, Inbred C57BL
Mice, Transgenic
Microglia
Microglia - pathology
Movement disorders
Nerve Degeneration - drug therapy
Nerve Degeneration - pathology
Nervous System Diseases - pathology
Neurodegenerative diseases
neuroinflammation
Neurotoxicity
nonmotor deficits
oligomeropathies
Parkinson Disease - metabolism
Parkinson Disease - pathology
Parkinson's disease
Phenotypes
Substantia Nigra - drug effects
Substantia Nigra - pathology
Synuclein
Transgenic mice
α‐synuclein oligomers
title Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T11%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20inflammation%20exacerbates%20%CE%B1%E2%80%90synuclein%20toxicity%20and%20neuropathology%20in%20Parkinson's%20models&rft.jtitle=Neuropathology%20and%20applied%20neurobiology&rft.au=La%20Vitola,%20P.&rft.date=2021-02&rft.volume=47&rft.issue=1&rft.spage=43&rft.epage=60&rft.pages=43-60&rft.issn=0305-1846&rft.eissn=1365-2990&rft_id=info:doi/10.1111/nan.12644&rft_dat=%3Cproquest_cross%3E2426177441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2482316939&rft_id=info:pmid/32696999&rfr_iscdi=true